Long non‑coding RNA TMPO‑AS1 facilitates chemoresistance and invasion in breast cancer by modulating the miR‑1179/TRIM37 axis

Ning,Xiaojie; Zhao,Jianguo; He,Fan; Yuan,Yuan; Li,Bin; Ruan,Jian

doi:10.3892/ol.2021.12761

Long non‑coding RNA TMPO‑AS1 facilitates chemoresistance and invasion in breast cancer by modulating the miR‑1179/TRIM37 axis

Authors:
- Xiaojie Ning
- Jianguo Zhao
- Fan He
- Yuan Yuan
- Bin Li
- Jian Ruan
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Wuhan Number 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: April 28, 2021 https://doi.org/10.3892/ol.2021.12761
Article Number: 500
Copyright: © Ning et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer has become the most common female tumor in the world. Although great progress has been made in the past decade, the treatment of advanced breast cancer remains unsatisfactory. An increasing number of reports have indicated that long non‑coding RNAs (lncRNAs) have a pivotal role in chemoresistance as potential oncogenes in numerous types of cancer. However, the precise mechanisms underlying the action of lncRNAs in breast cancer resistance to chemotherapy have yet to be fully elucidated. In the present study, the function and molecular mechanisms of the lncRNA TMPO‑antisense RNA 1 (AS1) in terms of its resistance to docetaxel (DOC) were explored in the MDA‑MB‑231 and MCF7 breast cancer cell lines. The results obtained suggested that TMPO‑AS1 was markedly upregulated in DOC‑resistant breast cancer cells compared with the sensitive breast cancer cells. Functionally, TMPO‑AS1‑knockdown sensitized MDA‑231/DOC and MCF‑7/DOC cells to DOC and suppressed cell invasion, with increased rates of DOC‑induced apoptosis. Mechanistically, TMPO‑AS1‑downregulation induced DOC‑sensitivity in breast cancer cells via depleting tripartite motif‑containing protein 37 (TRIM37) by sponging microRNA (miR)‑1179. Taken together, the present study has revealed the existence of a novel TMPO‑AS1/miR‑1179/TRIM37 molecular axis conferring DOC resistance of breast cancer cells, thereby suggesting a promising novel therapeutic target for breast cancer.

View Figures

View References

1	Merino Bonilla JA, Torres Tabanera M and Ros Mendoza LH: Breast cancer in the 21st century: From early detection to new therapies. Radiologia. 59:368–379. 2017.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
2	Fan L, Strasser Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
3	Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, et al: NCCN guidelines insights: Breast cancer, version 3.2018. J Natl Compr Canc Netw. 17:118–126. 2019. View Article : Google Scholar : PubMed/NCBI
4	Yang M, Li Y, Shen X, Ruan Y, Lu Y, Jin X, Song P, Guo Y, Zhang X, Qu H, et al: CLDN6 promotes chemoresistance through GSTP1 in human breast cancer. J Exp Clin Cancer Res. 36:1572017. View Article : Google Scholar : PubMed/NCBI
5	Jarroux J, Morillon A and Pinskaya M: History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 1008:1–46. 2017. View Article : Google Scholar : PubMed/NCBI
6	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
7	Peng WX, Koirala P and Mo YY: LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
8	Xiao J, Lv Y, Jin F, Liu Y, Ma Y, Xiong Y, Liu L, Zhang S, Sun Y, Tipoe GL, et al: LncRNA HANR promotes tumorigenesis and increase of chemoresistance in hepatocellular carcinoma. Cell Physiol Biochem. 43:1926–1938. 2017. View Article : Google Scholar : PubMed/NCBI
9	Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, Yu ZW, Jia YH, Bai XF, Li L, et al: The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Mol Cancer. 16:92017. View Article : Google Scholar : PubMed/NCBI
10	YiRen H, YingCong Y, Sunwu Y, Keqin L, Xiaochun T, Senrui C, Ende C, XiZhou L and Yanfan C: Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 16:1742017. View Article : Google Scholar : PubMed/NCBI
11	Fang Z, Zhao J, Xie W, Sun Q, Wang H and Qiao B: LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. Cancer Med. 6:2897–2908. 2017. View Article : Google Scholar : PubMed/NCBI
12	Li DS, Ainiwaer JL, Sheyhiding I, Zhang Z and Zhang LW: Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 20:2285–2295. 2016.PubMed/NCBI
13	Peng F, Wang R, Zhang Y, Zhao Z, Zhou W, Chang Z, Liang H, Zhao W, Qi L, Guo Z and Gu Y: Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer. 16:982017. View Article : Google Scholar : PubMed/NCBI
14	Huang W, Su X, Yan W, Kong Z, Wang D, Huang Y, Zhai Q, Zhang X, Wu H, Li Y, et al: Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer. Prostate. 78:1248–1261. 2018. View Article : Google Scholar : PubMed/NCBI
15	Bhatnagar S and Green MR: TRIMming down tumor suppressors in breast cancer. Cell Cycle. 14:1345–1346. 2015. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Lu Y, Yang Y and Liu Y, Hao Y, Zhang Y, Hu Y, Jiang L, Gong Y, Wu K and Liu Y: Upregulation of PAG1/Cbp contributes to adipose-derived mesenchymal stem cells promoted tumor progression and chemoresistance in breast cancer. Biochem Biophys Res Commun. 494:719–727. 2017. View Article : Google Scholar : PubMed/NCBI
18	Guttman M and Rinn JL: Modular regulatory principles of large non-coding RNAs. Nature. 482:339–346. 2012. View Article : Google Scholar : PubMed/NCBI
19	Gooding AJ, Zhang B, Gunawardane L, Beard A, Valadkhan S and Schiemann WP: The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers. Oncogene. 38:2020–2041. 2019. View Article : Google Scholar : PubMed/NCBI
20	Dong H, Wang W, Mo S, Chen R, Zou K, Han J, Zhang F and Hu J: SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88. J Exp Clin Cancer Res. 37:2022018. View Article : Google Scholar : PubMed/NCBI
21	Wang R, Zhang T, Yang Z, Jiang C and Seng J: Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. J Cell Mol Med. 22:4068–4075. 2018. View Article : Google Scholar : PubMed/NCBI
22	Jiang B, Li Y, Qu X, Zhu H, Tan Y, Fan Q, Jiang Y, Liao M and Wu X: Long noncoding RNA cancer susceptibility candidate 9 promotes doxorubicin-resistant breast cancer by binding to enhancer of zeste homolog 2. Int J Mol Med. 42:2801–2810. 2018.PubMed/NCBI
23	Wei L, Liu Y, Zhang H, Ma Y, Lu Z, Gu Z and Ding C: TMPO-AS1, a novel E2F1-regulated lncRNA, contributes to the proliferation of lung adenocarcinoma cells via modulating miR-326/SOX12 axis. Cancer Manag Res. 12:12403–12414. 2020. View Article : Google Scholar : PubMed/NCBI
24	Ding B, Lou W, Xu L and Fan W: Non-coding RNA in drug resistance of hepatocellular carcinoma. Biosci Rep. 38:BSR201809152018. View Article : Google Scholar : PubMed/NCBI
25	Sun ZY, Jian YK, Zhu HY and Li B: lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol Res Pract. 215:555–563. 2019. View Article : Google Scholar : PubMed/NCBI
26	Xu F, Zha G, Wu Y, Cai W and Ao J: Overexpressing lncRNA SNHG16 inhibited HCC proliferation and chemoresistance by functionally sponging hsa-miR-93. Onco Targets Ther. 11:8855–8863. 2018. View Article : Google Scholar : PubMed/NCBI
27	Gang X, Yuan M and Zhang J: Long non-coding RNA TMPO-AS1 promotes cervical cancer cell proliferation, migration, and invasion by regulating miR-143-3p/ZEB1 axis. Cancer Manag Res. 12:1587–1599. 2020. View Article : Google Scholar : PubMed/NCBI
28	Li WJ, Xie XX, Bai J, Wang C, Zhao L and Jiang DQ: Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis. Eur Rev Med Pharmacol Sci. 22:8374–8382. 2018.PubMed/NCBI
29	Lin C, Hu Z, Yuan G, Su H, Zeng Y, Guo Z, Zhong F, Jiang K and He S: MicroRNA-1179 inhibits the proliferation, migration and invasion of human pancreatic cancer cells by targeting E2F5. Chem Biol Interact. 291:65–71. 2018. View Article : Google Scholar : PubMed/NCBI
30	Jiang J, Yu C, Chen M, Tian S and Sun C: Over-expression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/β-catenin signaling. Biochem Biophys Res Commun. 464:1120–1127. 2015. View Article : Google Scholar : PubMed/NCBI
31	Hu CE and Gan J: TRIM37 promotes epithelial-mesenchymal transition in colorectal cancer. Mol Med Rep. 15:1057–1062. 2017. View Article : Google Scholar : PubMed/NCBI
32	Bhatnagar S, Gazin C, Chamberlain L, Ou J, Zhu X, Tushir JS, Virbasius CM, Lin L, Zhu LJ, Wajapeyee N and Green MR: TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein. Nature. 516:116–120. 2014. View Article : Google Scholar : PubMed/NCBI